In colorectal cancer, Wei et al. confirmed that zebularine, a DNMT inhibitor with low toxicity, overcomes hypoxia-induced resistance to oxaliplatin in HCT116 cells by down-regulating the expression of hypoxia-inducible factor-1α (HIF-1α). This evidence concerns the gene HIF1A and colorectal cancer.